Recent Advances in Cancer Care — New Paradigms, Novel Agents and What It Means for the Oncology Nurse: Management of Relapsed/Refractory Multiple Myeloma

Faculty

Program Schedule — Central Time

11:45 AM – 12:15 PM — Registration and Lunch
12:15 PM – 1:45 PM — Educational Meeting

MODULE 1: Role of Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory (R/R) Multiple Myeloma (MM)

• Rationale for targeting B-cell maturation antigen (BCMA) with CAR T-cell therapy for MM
• Research database documenting the effectiveness of idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) for heavily pretreated MM
• Available data with and FDA approvals of ide-cel and cilta-cel in earlier settings; overall survival (OS) advantage documented with cilta-cel
• Identification of appropriate candidates for BCMA-targeted CAR T-cell therapy and optimal sequencing of this strategy opposite other evidence-based approaches
• Early data with and ongoing evaluation of CAR T-cell platforms with targets beyond BCMA (eg, the GPRC5D-directed agent arlocabtagene autoleucel)

MODULE 2: Tolerability and Other Practical Considerations with CAR T-Cell Therapy

• Overview of the CAR T-cell manufacturing and delivery processes
• Incidence, timing and signs and symptoms of cytokine release syndrome (CRS), neurotoxicity or immune effector cell-associated neurotoxicity syndrome (ICANS) and other acute adverse events (AEs) with CAR T-cell therapy; optimal patient monitoring after infusion
• Guideline-endorsed approaches for mitigation and management of CRS, neurotoxicity/ICANS and other AEs with CAR T-cell therapy; role of corticosteroids, tocilizumab and other supportive care interventions
• Educating patients about practical requirements after CAR T-cell infusion (eg, the need to remain within proximity of the treatment center, recommendations regarding driving); implications of the recent elimination of the Risk Evaluation and Mitigation Strategy program for CAR T-cell therapy
• Potential for long-term tolerability/toxicity concerns (eg, delayed neurotoxicity, prolonged cytopenias, hypogammaglobulinemia, infections, secondary malignancies) with CAR T-cell therapy

MODULE 3: Role of B-Cell Maturation Antigen (BCMA)- and Non-BCMA-Targeted Bispecific Antibodies for MM

• Mechanistic similarities and differences between bispecific antibodies and CAR T-cell therapy; targets of various approved bispecific antibodies (eg, teclistamab, elranatamab, linvoseltamab, talquetamab)
• Long-term outcomes observed in pivotal trials of the BCMA-targeted bispecific antibodies teclistamab and elranatamab for heavily pretreated MM
• Efficacy and safety data leading to the FDA approval of the anti-BCMA bispecific antibody linvoseltamab for R/R MM
• Available efficacy and safety data with the non-BCMA-targeted bispecific antibody talquetamab for heavily pretreated disease
• Optimal selection of candidates with R/R MM for BCMA- and non-BCMA-targeted bispecific antibodies; considerations guiding the sequencing of these agents relative to other strategies and each other

MODULE 4: Toxicities and Practical Issues Related to Bispecific Antibodies

• Potential practical advantages of the “off-the-shelf” nature of bispecific antibodies
• Routes of administration, recommended dosing schedules and premedications with the various bispecific antibody platforms for MM; duration of hospitalization during step-up dosing
• Comparative tolerability of BCMA- and non-BCMA-directed bispecific antibodies for MM
• Incidence, severity and time course of CRS and neurotoxicity with bispecific antibodies; recommended protocols for mitigation and management
• Spectrum, frequency and management of other toxicities (eg, hepatotoxicity, infections, neutropenia, skin- and nail-related AEs, oral toxicities) reported with one or more bispecific antibodies

MODULE 5: Utility of Belantamab Mafodotin for R/R MM

• Mechanism of action and structural components of the BCMA-directed antibody-drug conjugate belantamab mafodotin
• Historical efficacy and safety findings with belantamab mafodotin monotherapy for patients with R/R MM; rationale for the withdrawal of this agent
• Key findings with belantamab mafodotin in combination with bortezomib/dexamethasone and pomalidomide/dexamethasone for patients who have received ≥1 prior line of therapy; OS advantage documented with the former combination
• Ongoing FDA review of belantamab mafodotin-based combination strategies; potential clinical role for R/R MM

MODULE 6: Tolerability Considerations with Belantamab Mafodotin

• Pathophysiology and symptomatology of the ocular AEs observed with belantamab mafodotin; impact of dosing on frequency and severity of ocular AEs
• Indications for and timing of ophthalmologic referral for patients about to receive belantamab mafodotin
• Optimal approaches to the management of ocular toxicities with belantamab mafodotin
• Spectrum, frequency, severity and management of other common and uncommon toxicities reported with belantamab mafodotin

MODULE 7: Potential Role of Cereblon E3 Ligase Modulators (CELMoDs) for MM

• Mechanism of action of the CELMoDs iberdomide and mezigdomide; similarities and differences between CELMoDs and standard immunomodulatory agents (IMiDs)
• Published efficacy and safety findings with iberdomide and mezigdomide as monotherapy and combined with other systemic therapies for pretreated MM
• Rationale for the use of minimal residual disease (MRD) negativity as a clinical trial endpoint for MM; emerging Phase III data indicating an improvement in MRD negativity rates with iberdomide/daratumumab/dexamethasone versus daratumumab/bortezomib/dexamethasone for R/R MM
• Other ongoing studies evaluating CELMoD-containing therapy for newly diagnosed and R/R MM; potential clinical role of CELMoDs

MODULE 8: Tolerability/Toxicity Considerations with CELMoDs for MM

• Comparative tolerability profiles of iberdomide, mezigdomide and traditional IMiDs
• Spectrum, frequency and severity of hematologic AEs observed with CELMoDs in published clinical studies
• Incidence and time course of nonhematologic complications (eg, gastrointestinal toxicities, cutaneous AEs, fatigue, infections, peripheral neuropathy) reported with CELMoDs
• Toxicity and tolerability of iberdomide and mezigdomide in combination with other effective antimyeloma therapies; strategies to discern the effects of each individual agent
• Appropriate monitoring, mitigation and management protocols for hematologic and nonhematologic side effects with CELMoDs

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of multiple myeloma.

Learning Objectives
Upon completion of this activity, participants should be able to

• Consider published research findings and other clinical factors that affect the best-practice selection, sequencing and combining of established agents and regimens in the care of patients with relapsed/refractory (R/R) multiple myeloma (MM).
• Evaluate the biological rationale for chimeric antigen receptor T-cell therapy directed at B-cell maturation antigen (BCMA) as a targeted therapeutic strategy in MM, and discuss with patients when and if this novel strategy should be considered.
• Educate patients with R/R MM about the mechanism of action of, available data with and current clinical role of BCMA- and non-BCMA-directed bispecific antibodies.
• Review recently presented clinical research findings establishing the definitive efficacy of BCMA-directed antibody-drug conjugate therapy, and recognize the potential clinical role of this form of treatment.
• Appreciate the mechanism of action of, unique characteristics of and available and emerging data with the various cereblon E3 ligase modulators under development, to prepare for their potential clinical availability for patients with R/R MM.
• Implement a plan of care to recognize and manage side effects and toxicities associated with commonly used, recently approved and promising emerging systemic therapies for MM.

Accreditation Statement
Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1.5 contact hours is provided by Research To Practice.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. To review certification qualifications please visit https://researchtopractice.com/Meetings/ONS2026/RRMultipleMyeloma/ILNA.

ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

Credit Form
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures will be provided.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Faiman — Advisory Committees and Consulting Agreements: Janssen Biotech Inc, Sanofi. Dr Lee — Consulting Agreements (Paid to Institution): AbbVie Inc, Alexion Pharmaceuticals, Allogene Therapeutics, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, GSK, Janssen Biotech Inc, Legend Biotech, Medline, Pfizer Inc, Predicta Biosciences, Regeneron Pharmaceuticals Inc, Sanofi, Takeda Pharmaceuticals USA Inc; Consulting Agreements (Paid to Self): Alexion Pharmaceuticals, Allogene Therapeutics, Bristol Myers Squibb, GSK, Janssen Biotech Inc, Menarini Group, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi, Takeda Pharmaceuticals USA Inc; Contracted Research: AbbVie Inc, Alexion Pharmaceuticals, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, GSK, Janssen Biotech Inc, Menarini Group, Moderna, Regeneron Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Data and Safety Monitoring Boards/Committees: Allogene Therapeutics, Takeda Pharmaceuticals USA Inc. Dr Steinbach — Advisory Committees: Bristol Myers Squibb, Johnson & Johnson, Pfizer Inc, Regeneron Pharmaceuticals Inc; Contracted Research and Speakers Bureaus: Johnson & Johnson, Pfizer Inc, Regeneron Pharmaceuticals Inc.

MODERATOR — Dr Callander has no relevant financial relationships to disclose.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from Bristol Myers Squibb, GSK, and Regeneron Pharmaceuticals Inc.

Location
San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, TX 78205
Hotel Phone: (210) 223-1000

Meeting Room
Grand Ballroom A-F (Third Floor)

Directions
The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center, where the 2026 ONS Congress is taking place.

Registration is now closed.